BioXcel Therapeutics, Inc.
BTAI
$1.31
$0.064.80%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 206.00K | 256.00K | 98.00K | 120.00K | 168.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 206.00K | 256.00K | 98.00K | 120.00K | 168.00K |
| Cost of Revenue | 283.00K | 32.00K | 11.00K | 107.00K | 14.00K |
| Gross Profit | -77.00K | 224.00K | 87.00K | 13.00K | 154.00K |
| SG&A Expenses | 7.19M | 3.81M | 5.38M | 5.61M | 5.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.43M | 10.54M | 14.13M | 15.97M | 10.27M |
| Operating Income | -10.22M | -10.28M | -14.03M | -15.85M | -10.10M |
| Income Before Tax | -12.69M | -12.55M | -30.91M | -19.19M | -7.25M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.69M | -12.55M | -30.91M | -19.19M | -7.25M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.69M | -12.55M | -30.91M | -19.19M | -7.25M |
| EBIT | -10.22M | -10.28M | -14.03M | -15.85M | -10.10M |
| EBITDA | -10.17M | -10.21M | -13.96M | -15.78M | -10.02M |
| EPS Basic | -0.54 | -0.57 | -2.18 | -2.45 | -1.50 |
| Normalized Basic EPS | -0.34 | -0.36 | -1.35 | -1.53 | -0.94 |
| EPS Diluted | -0.54 | -0.57 | -2.18 | -2.45 | -1.50 |
| Normalized Diluted EPS | -0.34 | -0.36 | -1.35 | -1.53 | -0.94 |
| Average Basic Shares Outstanding | 23.57M | 21.86M | 14.20M | 7.84M | 4.83M |
| Average Diluted Shares Outstanding | 23.57M | 21.86M | 14.20M | 7.84M | 4.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |